The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.
Georg Pfeiler
Honoraria - Novartis
Robert Konigsberg
No relevant relationships to disclose
Christian Fesl
No relevant relationships to disclose
Brigitte Mlineritsch
No relevant relationships to disclose
Herbert Stoger
No relevant relationships to disclose
Christian F. Singer
Honoraria - AstraZeneca; MSD
Sabine Poestlberger
Honoraria - AstraZeneca; Novartis; Roche
Guenther G. Steger
Honoraria - Amgen; AstraZeneca; Novartis; Roche
Michael Seifert
Honoraria - AstraZeneca; Novartis
Peter Christian Dubsky
Honoraria - Genomic Health; Novartis; Pfizer; Roche
Raimund Jakesz
Consultant or Advisory Role - AstraZeneca; Roche; Sanofi
Honoraria - AstraZeneca; Novartis; Roche
Hellmut Samonigg
Consultant or Advisory Role - AstraZeneca; Celgene; Eisai; Takeda
Honoraria - Amgen; AstraZeneca; Janssen-Cilag; Merck; Novartis; Pfizer; Roche
Vesna Bjelic-Radisic
No relevant relationships to disclose
Richard Greil
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - AstraZeneca; Novartis
Christian Marth
Honoraria - Novartis
Michael Gnant
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Honoraria - Amgen; AstraZeneca; Novartis; Pfizer; Roche; Sanofi ; Schering-Plough